JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 86.7%

Neg 86.7% Neu 0% Pos 0%

JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.